Cargando…
Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection?
BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654059/ https://www.ncbi.nlm.nih.gov/pubmed/29061125 http://dx.doi.org/10.1186/s12885-017-3671-0 |
_version_ | 1783273335159783424 |
---|---|
author | Zhu, Menghan Jia, Nan Huang, Feifei Liu, Xiaoxia Zhao, Yuqing Tao, Xiang Jiang, Wei Li, Qin Feng, Weiwei |
author_facet | Zhu, Menghan Jia, Nan Huang, Feifei Liu, Xiaoxia Zhao, Yuqing Tao, Xiang Jiang, Wei Li, Qin Feng, Weiwei |
author_sort | Zhu, Menghan |
collection | PubMed |
description | BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter ≥ 2 cm and 818 low-risk patients with grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter < 2 cm were enrolled in this study. The rate and risk factors of node metastasis were evaluated and compared between the two risk groups. Survival data were analyzed in patients with intermediate-risk EEC with or without lymphadenectomy. RESULTS: In all, 624 of 1009 (61.8%) patients with intermediate-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 1.9% (12/624), whereas 394 of 818 (48.2%) patients with low-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 0.3% (1/394) (p = 0.021). Notably, intermediate-risk EEC patients with a microcystic, elongated and fragmented (MELF) pattern of invasion, lymphatic vascular space invasion (LVSI), diffuse lesions, or lesions located in the cornua were more likely to have node metastasis. The 5-year overall cancer-related survival and the recurrence-free survival rates of the 742 intermediate-risk EEC patients who were followed for more than 3 years were 99.4% and 94.7%, respectively. In intermediate-risk group, 6 patients (6/443, 1.4%) with lymphadenectomy and 9 patients (9/299, 3.0%) without lymphadenectomy recurred, with a mean recurrence time of 38.3 and 18.7 months respectively. The five-year overall and recurrence-free survival rates of intermediate-risk patients with and without lymphadenectomy were similar (100% vs 98.9%, p = 0.351; 95.2% vs 93.3%, p = 0.464). CONCLUSION: Patients with intermediate-risk EEC have low nodal metastasis rate and a favorable outcome whether lymphadenectomy is performed or not. Omission of lymphadenectomy may be a reasonable option in the surgical management of patients with intermediate-risk EEC. |
format | Online Article Text |
id | pubmed-5654059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-56540592017-10-26 Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? Zhu, Menghan Jia, Nan Huang, Feifei Liu, Xiaoxia Zhao, Yuqing Tao, Xiang Jiang, Wei Li, Qin Feng, Weiwei BMC Cancer Research Article BACKGROUND: Our research aimed to investigate whether lymphadenectomy was required in patients with intermediate-risk endometrioid endometrial cancer (EEC). METHODS: Between 1989 and 2015, 1009 patients with intermediate-risk EEC: grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter ≥ 2 cm and 818 low-risk patients with grade 1 or 2 tumor, <50% myometrial invasion, and a tumor diameter < 2 cm were enrolled in this study. The rate and risk factors of node metastasis were evaluated and compared between the two risk groups. Survival data were analyzed in patients with intermediate-risk EEC with or without lymphadenectomy. RESULTS: In all, 624 of 1009 (61.8%) patients with intermediate-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 1.9% (12/624), whereas 394 of 818 (48.2%) patients with low-risk EEC underwent pelvic ± para-aortic lymphadenectomy with a nodal metastasis rate of 0.3% (1/394) (p = 0.021). Notably, intermediate-risk EEC patients with a microcystic, elongated and fragmented (MELF) pattern of invasion, lymphatic vascular space invasion (LVSI), diffuse lesions, or lesions located in the cornua were more likely to have node metastasis. The 5-year overall cancer-related survival and the recurrence-free survival rates of the 742 intermediate-risk EEC patients who were followed for more than 3 years were 99.4% and 94.7%, respectively. In intermediate-risk group, 6 patients (6/443, 1.4%) with lymphadenectomy and 9 patients (9/299, 3.0%) without lymphadenectomy recurred, with a mean recurrence time of 38.3 and 18.7 months respectively. The five-year overall and recurrence-free survival rates of intermediate-risk patients with and without lymphadenectomy were similar (100% vs 98.9%, p = 0.351; 95.2% vs 93.3%, p = 0.464). CONCLUSION: Patients with intermediate-risk EEC have low nodal metastasis rate and a favorable outcome whether lymphadenectomy is performed or not. Omission of lymphadenectomy may be a reasonable option in the surgical management of patients with intermediate-risk EEC. BioMed Central 2017-10-23 /pmc/articles/PMC5654059/ /pubmed/29061125 http://dx.doi.org/10.1186/s12885-017-3671-0 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhu, Menghan Jia, Nan Huang, Feifei Liu, Xiaoxia Zhao, Yuqing Tao, Xiang Jiang, Wei Li, Qin Feng, Weiwei Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title | Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title_full | Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title_fullStr | Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title_full_unstemmed | Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title_short | Whether intermediate-risk stage 1A, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
title_sort | whether intermediate-risk stage 1a, grade 1/2, endometrioid endometrial cancer patients with lesions larger than 2 cm warrant lymph node dissection? |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5654059/ https://www.ncbi.nlm.nih.gov/pubmed/29061125 http://dx.doi.org/10.1186/s12885-017-3671-0 |
work_keys_str_mv | AT zhumenghan whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT jianan whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT huangfeifei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT liuxiaoxia whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT zhaoyuqing whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT taoxiang whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT jiangwei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT liqin whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection AT fengweiwei whetherintermediateriskstage1agrade12endometrioidendometrialcancerpatientswithlesionslargerthan2cmwarrantlymphnodedissection |